New combo therapy shows promise for advanced breast cancer
NCT ID NCT02767661
First seen Feb 28, 2026 · Last updated Jun 14, 2026 · Updated 12 times
Summary
This study tested whether adding a low-dose chemotherapy drug (capecitabine) to standard hormone therapy (aromatase inhibitor) works better than hormone therapy alone for women with a common type of advanced breast cancer (HR+/HER2-). The trial involved 263 women who had not yet received treatment for their advanced disease. The main goal was to see if the combination could delay cancer growth or death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.